MERCK Kommanditgesellschaft auf Aktien
Market Cap
€45.3b
Last Updated
2019/10/14 21:20 UTC
Data Sources
Company Financials +
Executive Summary
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide.
Snowflake
Fundamentals
Adequate balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has MERCK Kommanditgesellschaft auf Aktien's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.6%
MRCK
0.9%
AT Pharmaceuticals
1.8%
AT Market
1 Year Return
n/a
MRCK
12.0%
AT Pharmaceuticals
-4.1%
AT Market
Return vs Industry: Insufficient data to determine how MRCK performed against the Austrian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MRCK performed against the Austrian Market.
Share holder returns
| MRCK | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.6% | 0.9% | 1.8% |
| 30 Day | 5.1% | 2.2% | -1.3% |
| 90 Day | 12.7% | 6.2% | 0.1% |
| 1 Year | n/a | 18.4%12.0% | -0.6%-4.1% |
| 3 Year | n/a | 30.4%15.9% | 44.3%31.2% |
| 5 Year | n/a | 35.0%12.8% | 69.5%45.1% |
Price Volatility Vs. Market
How volatile is MERCK Kommanditgesellschaft auf Aktien's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is MERCK Kommanditgesellschaft auf Aktien undervalued based on future cash flows and its price relative to the stock market?
1%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Undervalued: MRCK (€104.1) is trading below our estimate of fair value (€105.49)
Significantly Undervalued: MRCK is trading below fair value, but not by a significant amount.
Price Based on Earnings
PE vs Industry: MRCK is poor value based on its PE Ratio (40.5x) compared to the Pharmaceuticals industry average (22.9x).
PE vs Market: MRCK is poor value based on its PE Ratio (40.5x) compared to the Austrian market (14.1x).
Price Based on Expected Growth
Low PEG Ratio: MRCK is poor value based on its PEG Ratio (3x)
Price Based on Value of Assets
PB vs Industry: MRCK is good value based on its PB Ratio (2.6x) compared to the XE Pharmaceuticals industry average (2.9x).
Next Steps
Future Growth
How is MERCK Kommanditgesellschaft auf Aktien expected to perform in the next 1 to 3 years based on estimates from 21 analysts?
13.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Earnings vs Savings Rate: MRCK's forecast earnings growth (13.6% per year) is above the savings rate (0.5%).
Earnings vs Market: MRCK's earnings (13.6% per year) are forecast to grow faster than the Austrian market (8.2% per year).
High Growth Earnings: MRCK's earnings are forecast to grow, but not significantly.
Revenue vs Market: MRCK's revenue (5% per year) is forecast to grow faster than the Austrian market (3% per year).
High Growth Revenue: MRCK's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Estimates
Future Return on Equity
High Future ROE: MRCK's Return on Equity is forecast to be low in 3 years time (12.2%).
Next Steps
Past Performance
How has MERCK Kommanditgesellschaft auf Aktien performed over the past 5 years?
7.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: MRCK's earnings have grown by 7.3% per year over the past 5 years.
Accelerating Growth: MRCK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MRCK had negative earnings growth (-49.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.7%).
Return on Equity
High ROE: MRCK's Return on Equity (6.5%) is considered low.
Return on Assets
ROA vs Industry: MRCK's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: MRCK's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is MERCK Kommanditgesellschaft auf Aktien's financial position?
Financial Position Analysis
Short Term Liabilities: MRCK's short term assets (€11.7B) exceeds its short term liabilities (€10.5B)
Long Term Liabilities: MRCK's short term assets (11.7B) exceeds its long term liabilities (11.5B)
Debt to Equity History and Analysis
Debt Level: MRCK's debt to equity ratio (62.6%) is considered high
Reducing Debt: MRCK's debt to equity ratio has increased from 35.8% to 62.6% over the past 5 years.
Debt Coverage: MRCK's debt is well covered by operating cash flow (24.6%).
Interest Coverage: MRCK's interest payments on its debt are well covered by EBIT (8.6x coverage).
Balance Sheet
Inventory Level: MRCK has a high level of physical assets or inventory.
Debt Coverage by Assets: MRCK's debt is covered by short term assets (assets are 1.063090x debt).
Next Steps
Dividend
What is MERCK Kommanditgesellschaft auf Aktien's current dividend yield, its reliability and sustainability?
1.36%
Expected Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Dividend Yield and Payments Analysis
Notable Dividend: MRCK's dividend (1.2%) isn’t notable compared to the bottom 25% of dividend payers in the Austrian market (1.58%).
High Dividend: MRCK's dividend (1.2%) is low compared to the top 25% of dividend payers in the Austrian market (4.48%).
Stable Dividend: MRCK's dividend payments have been volatile in the past 10 years.
Growing Dividend: MRCK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48.6%), MRCK's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: MRCK's dividends in 3 years are forecast to be well covered by earnings (21.9% payout ratio).
Next Steps
Management
What is the CEO of MERCK Kommanditgesellschaft auf Aktien's salary, the management and board of directors tenure and is there insider trading?
5.1yrs
Average management tenure
CEO
Stefan Oschmann (62yo)
3.5yrs
Tenure
€7,981,000
Compensation
Dr. Stefan Oschmann has been the Chairman of Executive Board and Chief Executive Officer of Merck KGaA since April 30, 2016. Dr. Oschmann has been a Member of Executive Board for Merck KGaA since January 1 ...
CEO Compensation Analysis
Compensation vs. Market: Insufficient data to establish whether Stefan's total compensation is reasonable compared to companies of similar size in the Austrian market.
Compensation vs Earnings: Stefan's compensation has been consistent with company performance over the past year.
Management Age and Tenure
5.1yrs
Average Tenure
51yo
Average Age
Experienced Management: MRCK's management team is seasoned and experienced (5.1 years average tenure).
Board Age and Tenure
10.3yrs
Average Tenure
63yo
Average Age
Experienced Board: MRCK's board of directors are seasoned and experienced ( 10.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Belén Garijo López (59yo)
CEO of Healthcare & Member of the Executive Board
- Tenure: 4.8yrs
- Compensation: €6.64m
Stefan Oschmann (62yo)
Chairman of Executive Board & CEO
- Tenure: 3.5yrs
- Compensation: €7.98m
Marcus Kuhnert (51yo)
CFO & Member of Executive Board
- Tenure: 5.4yrs
- Compensation: €4.38m
Kai Beckmann (54yo)
CEO of Performance Materials & Member of the Executive Board
- Tenure: 8.5yrs
- Compensation: €4.78m
Udit Batra (48yo)
CEO of Life Science & Member of Executive Board
- Tenure: 3.5yrs
- Compensation: €5.32m
Friederike Rotsch (47yo)
Group General Counsel and Head of Group Legal & Compliance
- Tenure: 5.5yrs
Constantin Fest (42yo)
Head of Investor Relations
- Tenure: 6.8yrs
Gerhard Schmitz (56yo)
Head of Global Accounting
- Tenure: 5.9yrs
Barbara Weiland (45yo)
Chief Compliance Officer
- Tenure: 0.3yrs
Dirk Toepfer
Chief Information Officer
- Tenure: 1.6yrs
Board Members
Michael Fletterich (61yo)
Vice Chairman of Supervisory Board
- Tenure: 5.4yrs
- Compensation: €72.75k
Theo Siegert (72yo)
Member of Supervisory Board
- Tenure: 13.3yrs
- Compensation: €49.25k
Albrecht Merck (69yo)
Member of Supervisory Board
- Tenure: 14.8yrs
- Compensation: €50.00k
Edeltraud Glänzer (64yo)
Member of Supervisory Board
- Tenure: 11.6yrs
- Compensation: €50.00k
Michaela von Glenck (73yo)
Member of Supervisory Board
- Tenure: 11.6yrs
- Compensation: €50.00k
Mechthild Auge (62yo)
Member of Supervisory Board
- Tenure: 10.6yrs
- Compensation: €50.00k
Wolfgang Büchele (60yo)
Chairman of Supervisory Board
- Tenure: 5.4yrs
- Compensation: €97.00k
Crocifissa Attardo (57yo)
Member of Supervisory Board
- Tenure: 10yrs
- Compensation: €50.00k
Helga Rübsamen-Schaeff (70yo)
Member of Supervisory Board
- Tenure: 5.4yrs
- Compensation: €50.00k
Tobias Thelen (43yo)
Member of Supervisory Board
- Tenure: 5.4yrs
- Compensation: €50.00k
Company Information
MERCK Kommanditgesellschaft auf Aktien's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MERCK Kommanditgesellschaft auf Aktien
- Ticker: MRCK
- Exchange: WBAG
- Founded: 1668
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €45.282b
- Shares outstanding: 434.78m
- Website: https://www.merckgroup.com
Number of Employees
Location
- MERCK Kommanditgesellschaft auf Aktien
- Frankfurter Strasse 250
- Darmstadt
- Hessen
- 64293
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MKGA.F | OTCPK (Pink Sheets LLC) | Yes | Bearer Shares | US | USD | Oct 1995 |
| MRK | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Oct 1995 |
| MRK | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Oct 1995 |
| 0O14 | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Oct 1995 |
| MRKD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Oct 1995 |
| MRCK | WBAG (Wiener Boerse AG) | Yes | Bearer Shares | AT | EUR | Oct 1995 |
| MER | SWX (SIX Swiss Exchange) | Yes | Bearer Shares | CH | CHF | Oct 1995 |
| MRK | BIT (Borsa Italiana) | Yes | Bearer Shares | IT | EUR | Oct 1995 |
| MKKG.Y | OTCPK (Pink Sheets LLC) | SPON ADR EACH REPR 0.2 ORD SHS | US | USD | Sep 2007 | |
| MRKC | BST (Boerse-Stuttgart) | SPON ADR EACH REPR 0.2 ORD SHS | DE | EUR | Sep 2007 |
Biography
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertili ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/14 21:20 |
| End of Day Share Price | 2019/10/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.